| scholarly article | Q13442814 |
| P2093 | author name string | David H Au | |
| Mary B McDonell | |||
| Jason W Chien | |||
| Tanyalak Parimon | |||
| Chris L Bryson | |||
| Edmunds M Udris | |||
| P2860 | cites work | Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial | Q24642534 |
| Inflammation and cancer | Q24649640 | ||
| Inflammation and cancer: back to Virchow? | Q28036756 | ||
| Chronic Chlamydophila pneumoniae infection in lung cancer, a risk factor: a case-control study | Q28187854 | ||
| The AUDIT alcohol consumption questions (AUDIT-C): an effective brief screening test for problem drinking. Ambulatory Care Quality Improvement Project (ACQUIP). Alcohol Use Disorders Identification Test | Q28282539 | ||
| Effects of fluticasone on systemic markers of inflammation in chronic obstructive pulmonary disease | Q44960162 | ||
| Budesonide exerts its chemopreventive efficacy during mouse lung tumorigenesis by modulating gene expressions | Q45054533 | ||
| A randomized phase IIb trial of pulmicort turbuhaler (budesonide) in people with dysplasia of the bronchial epithelium. | Q45099303 | ||
| The interrelationship between markers of inflammation and oxidative stress in chronic obstructive pulmonary disease: modulation by inhaled steroids and antioxidant. | Q45268723 | ||
| Dietary phytoestrogens and lung cancer risk | Q46724620 | ||
| Antiinflammatory effects of salmeterol/fluticasone propionate in chronic obstructive lung disease | Q46902397 | ||
| Re: asthma and the risk of lung cancer. findings from the Adverse Childhood Experiences (ACE). | Q47601766 | ||
| Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. European Respiratory Society Study on Chronic Obstructive Pulmonary Disease | Q49083880 | ||
| Early lung cancer detection: results of the initial (prevalence) radiologic and cytologic screening in the Johns Hopkins study | Q50583436 | ||
| Screening for early lung cancer. Results of the Memorial Sloan-Kettering study in New York. | Q50588124 | ||
| Lung cancer: early events, early interventions: conference summary for the 46th Annual Thomas L Petty Aspen Lung Conference. | Q50743943 | ||
| Circulating levels of inflammatory markers and cancer risk in the health aging and body composition cohort. | Q51509450 | ||
| Airway inflammation in severe chronic obstructive pulmonary disease: relationship with lung function and radiologic emphysema. | Q51712216 | ||
| Chemoprevention of pulmonary carcinogenesis by aerosolized budesonide in female A/J mice. | Q53438605 | ||
| Effect of 1-year smoking cessation on airway inflammation in COPD and asymptomatic smokers | Q57892108 | ||
| Long-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: a randomised controlled trial | Q57956059 | ||
| Local and Systemic Inflammation in Patients with Chronic Obstructive Pulmonary Disease | Q59669053 | ||
| Effect of Smoking Reduction on Lung Cancer Risk | Q61875233 | ||
| Glucocorticoids Inhibit Lung Cancer Cell Growth through Both the Extracellular Signal-Related Kinase Pathway and Cell Cycle Regulators | Q63169470 | ||
| A general method of compliance assessment using centralized pharmacy records. Description and validation | Q68455320 | ||
| Higher risk of lung cancer in chronic obstructive pulmonary disease. A prospective, matched, controlled study | Q69607983 | ||
| Validity of the recording of ischaemic heart disease and chronic obstructive pulmonary disease in the Saskatchewan health care datafiles | Q71052500 | ||
| Early lung cancer detection: results of the initial (prevalence) radiologic and cytologic screening in the Mayo Clinic study | Q72395827 | ||
| Screening strategies for early detection of lung cancer: the time is now | Q73087993 | ||
| Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease | Q73341072 | ||
| CD8+ T-lymphocytes in peripheral airways of smokers with chronic obstructive pulmonary disease | Q74363422 | ||
| Screening for lung cancer | Q80879471 | ||
| Asthma and risk of death from lung cancer: NHANES II Mortality Study | Q81230835 | ||
| Smoking kills: experimental proof from the Lung Health Study | Q81401224 | ||
| Are COPD and lung cancer two manifestations of the same disease? | Q94461711 | ||
| Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary | Q29614692 | ||
| Smoldering and polarized inflammation in the initiation and promotion of malignant disease | Q29618034 | ||
| The nature of small-airway obstruction in chronic obstructive pulmonary disease | Q29618682 | ||
| Low lung function and incident lung cancer in the United States: data From the First National Health and Nutrition Examination Survey follow-up | Q30806378 | ||
| Lung cancer screening with sputum cytologic examination, chest radiography, and computed tomography: an update for the U.S. Preventive Services Task Force | Q31057585 | ||
| Growth in vascular cells and cytokine production by Chlamydia pneumoniae | Q33935046 | ||
| The early diagnosis of lung cancer | Q34319582 | ||
| The effects of a smoking cessation intervention on 14.5-year mortality: a randomized clinical trial | Q34394365 | ||
| Risk factors for lung cancer and for intervention effects in CARET, the Beta-Carotene and Retinol Efficacy Trial | Q34405938 | ||
| Chlamydia pneumoniae and lung cancer: epidemiologic evidence | Q34410654 | ||
| How DNA lesions are turned into mutations within cells? | Q35026386 | ||
| Sputum cytology for the detection of early lung cancer | Q35154292 | ||
| Effects of fluticasone propionate on inflammatory cells in COPD: an ultrastructural examination of endobronchial biopsy tissue | Q35535364 | ||
| COPD increases the risk of squamous histological subtype in smokers who develop non-small cell lung carcinoma | Q35536873 | ||
| Inhaled corticosteroids and mortality in chronic obstructive pulmonary disease | Q35537366 | ||
| Relationship between reduced forced expiratory volume in one second and the risk of lung cancer: a systematic review and meta-analysis | Q35537826 | ||
| Cyclooxygenase as a target in lung cancer | Q35817554 | ||
| Inhaled combination therapy with long-acting beta 2-agonists and corticosteroids in stable COPD. | Q35833977 | ||
| Mediators of chronic obstructive pulmonary disease | Q35985843 | ||
| Role of inflammation in mouse lung tumorigenesis: a review | Q36070436 | ||
| Relation between duration of smoking cessation and bronchial inflammation in COPD | Q36183908 | ||
| Update in screening of lung cancer | Q36305897 | ||
| Registration of lung cancer in Scotland: an assessment of data accuracy based on review of medical records | Q36680023 | ||
| Estimating causal effects from large data sets using propensity scores | Q36893066 | ||
| Chlamydia pneumoniae infection and risk of lung cancer. | Q37866340 | ||
| An association between chronic infection with Chlamydia pneumoniae and lung cancer. A prospective 2-year study | Q37872408 | ||
| Serological evidence of an association between Chlamydia pneumoniae infection and lung cancer | Q37883417 | ||
| Lung cancer detection in patients with airflow obstruction identified in a primary care outpatient practice | Q38474511 | ||
| Correlation of travel time on roads versus straight line distance | Q39494755 | ||
| The assessment of refill compliance using pharmacy records: methods, validity, and applications | Q41361915 | ||
| Comparison of inhaled corticosteroids | Q41718750 | ||
| The effects of inhaled fluticasone on airway inflammation in chronic obstructive pulmonary disease: a double-blind, placebo-controlled biopsy study | Q44031728 | ||
| Effectiveness of fluticasone propionate and salmeterol combination delivered via the Diskus device in the treatment of chronic obstructive pulmonary disease | Q44179168 | ||
| Effects of adrenalectomy and corticosterone administration on mouse lung tumor susceptibility and histogenesis | Q44260460 | ||
| Lung cancer prevention: the guidelines | Q44278151 | ||
| Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial | Q44313160 | ||
| The efficacy and safety of fluticasone propionate (250 microg)/salmeterol (50 microg) combined in the Diskus inhaler for the treatment of COPD. | Q44582263 | ||
| Cost-effectiveness of Screening for Lung Cancer | Q44604195 | ||
| Effect of chemopreventive agents on separate stages of progression of benzo[ ]pyrene induced lung tumors in A/J mice | Q44631701 | ||
| Effects of sustained audit/feedback on self-reported health status of primary care patients | Q44768172 | ||
| Validation of case-mix measures derived from self-reports of diagnoses and health | Q44810913 | ||
| P433 | issue | 7 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | lung cancer | Q47912 |
| chronic obstructive pulmonary disease | Q199804 | ||
| P304 | page(s) | 712-719 | |
| P577 | publication date | 2006-12-21 | |
| P1433 | published in | American Journal of Respiratory and Critical Care Medicine | Q4744267 |
| P1476 | title | Inhaled corticosteroids and risk of lung cancer among patients with chronic obstructive pulmonary disease | |
| P478 | volume | 175 |
| Q21131903 | "Sentinel" circulating tumor cells allow early diagnosis of lung cancer in patients with chronic obstructive pulmonary disease |
| Q50889106 | A major cause of death in COPD and risk factors for lung cancer a dilemma or a mistake? |
| Q33705875 | A randomized controlled trial of inhaled corticosteroids (ICS) on markers of epithelial-mesenchymal transition (EMT) in large airway samples in COPD: an exploratory proof of concept study |
| Q99565677 | Acute exacerbations of COPD and risk of lung cancer in COPD patients with and without a history of asthma |
| Q34065677 | Airway epithelial platelet-activating factor receptor expression is markedly upregulated in chronic obstructive pulmonary disease |
| Q92546031 | Allergies and Asthma in Relation to Cancer Risk |
| Q91606951 | Assessing the lung cancer risk reduction potential of candidate modified risk tobacco products |
| Q36540914 | Associated Links Among Smoking, Chronic Obstructive Pulmonary Disease, and Small Cell Lung Cancer: A Pooled Analysis in the International Lung Cancer Consortium |
| Q33288486 | Association between cancer prevalence and use of thiazolidinediones: results from the Vermont Diabetes Information System |
| Q34426740 | Association between common allergic symptoms and cancer in the NHANES III female cohort |
| Q34231742 | Budesonide versus placebo in high-risk population with screen-detected lung nodules: rationale, design and methodology |
| Q37739977 | COPD is commonly underdiagnosed in patients with lung cancer: results from the RECOIL study (retrospective study of COPD infradiagnosis in lung cancer). |
| Q37300835 | Cancer risk in patients with chronic obstructive pulmonary disease |
| Q37078797 | Characteristics of elderly patients with COPD and newly diagnosed lung cancer, and factors associated with treatment decision |
| Q83616295 | Chemoprevention of lung cancer |
| Q37111529 | Chemoprevention of lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines |
| Q28386632 | Chemoprevention of lung cancer: prospects and disappointments in human clinical trials |
| Q26774588 | Chemoprevention studies within lung cancer screening programmes |
| Q51109588 | Chemopreventive effect of phosphodieasterase-4 inhibition in benzo(a)pyrene-induced murine lung cancer model. |
| Q38255396 | Chronic Obstructive Pulmonary Disease (COPD) and Lung Cancer: Epithelial Mesenchymal Transition (EMT), the Missing Link? |
| Q58613950 | Chronic Obstructive Pulmonary Disease and Lung Cancer: Underlying Pathophysiology and New Therapeutic Modalities |
| Q37350689 | Chronic obstructive lung diseases and risk of non-small cell lung cancer in women |
| Q38169870 | Chronic obstructive pulmonary disease and comorbidities |
| Q34031235 | Chronic obstructive pulmonary disease as a risk factor for lung cancer |
| Q43217503 | Clinical significance of epithelial mesenchymal transition (EMT) in chronic obstructive pulmonary disease (COPD): potential target for prevention of airway fibrosis and lung cancer |
| Q36067911 | Combinations of indole-3-carbinol and silibinin suppress inflammation-driven mouse lung tumorigenesis by modulating critical cell cycle regulators |
| Q37834029 | Common pathogenic mechanisms and pathways in the development of COPD and lung cancer. |
| Q90399908 | Conventional Western Treatment Combined With Chinese Herbal Medicine Alleviates the Progressive Risk of Lung Cancer in Patients With Chronic Obstructive Pulmonary Disease: A Nationwide Retrospective Cohort Study |
| Q37316084 | Current concepts on the role of inflammation in COPD and lung cancer |
| Q28069762 | Do inhaled corticosteroids protect against lung cancer in patients with COPD? A systematic review |
| Q53236553 | Epithelial Mesenchymal Transition in Chronic Obstructive Pulmonary Disease, a Precursor for Epithelial Cancers: Understanding and Translation to Early Therapy. |
| Q35935002 | Epithelial mesenchymal transition in smokers: large versus small airways and relation to airflow obstruction |
| Q39395614 | Epithelial-mesenchymal transition, a spectrum of states: Role in lung development, homeostasis, and disease. |
| Q55315806 | Factors associated with lung cancer in COPD patients. |
| Q36148775 | Genetic variants associated with the risk of chronic obstructive pulmonary disease with and without lung cancer |
| Q26770177 | Glucocorticoid receptors in lung cancer: new perspectives |
| Q93209134 | Heparin-binding epidermal growth factor (HB-EGF) drives EMT in patients with COPD: implications for disease pathogenesis and novel therapies |
| Q59792625 | Impact of COPD on prognosis of lung cancer: from a perspective on disease heterogeneity |
| Q35897669 | Inflammation in chronic obstructive pulmonary disease and its role in cardiovascular disease and lung cancer |
| Q41196305 | Inhaled corticosteroid normalizes some but not all airway vascular remodeling in COPD. |
| Q43864628 | Inhaled corticosteroids and lung cancer chemoprevention |
| Q33728108 | Inhaled corticosteroids have a protective effect against lung cancer in female patients with chronic obstructive pulmonary disease: a nationwide population-based cohort study. |
| Q37681569 | Inhaled corticosteroids in chronic obstructive pulmonary disease: a review. |
| Q64885038 | Inhaled corticosteroids may prevent lung cancer in asthma patients. |
| Q35189528 | Is inflammatory chronic obstructive pulmonary disease a coronary heart disease risk equivalent? A longitudinal analysis of the third National Health and Nutrition Examination Survey (NHANES III), 1988-1994. |
| Q30239798 | Lung cancer and chronic obstructive pulmonary disease: From a clinical perspective |
| Q28754732 | Lung cancer and chronic obstructive pulmonary disease: needs and opportunities for integrated research |
| Q26995495 | Lung cancer chemoprevention: current status and future prospects |
| Q37823042 | Lung cancer in chronic obstructive pulmonary disease: enhancing surgical options and outcomes |
| Q24630167 | Lung cancer: epidemiology, etiology, and prevention |
| Q42913932 | Lung inflammatory effects, tumorigenesis, and emphysema development in a long-term inhalation study with cigarette mainstream smoke in mice |
| Q95641902 | Management of the COPD Patient with Comorbidities: An Experts Recommendation Document |
| Q34331434 | Mechanistic links between COPD and lung cancer |
| Q35669716 | Neutralization of tumor necrosis factor bioactivity ameliorates urethane-induced pulmonary oncogenesis in mice |
| Q37924598 | Pharmacological treatment of COPD. |
| Q37119224 | Post-Inhaled Corticosteroid Pulmonary Tuberculosis Increases Lung Cancer in Patients with Asthma |
| Q36159612 | Post-inhaled corticosteroid pulmonary tuberculosis and pneumonia increases lung cancer in patients with COPD |
| Q37098772 | Prospective study of inhaled corticosteroid use, cardiovascular mortality, and all-cause mortality in asthmatic women |
| Q34472750 | Randomized phase II trial of inhaled budesonide versus placebo in high-risk individuals with CT screen-detected lung nodules |
| Q38111793 | Recent advances in understanding inflammation and remodeling in the airways in chronic obstructive pulmonary disease |
| Q35240254 | Regular inhaled corticosteroids in adult-onset asthma and the risk for future cancer: a population-based cohort study with proper person-time analysis |
| Q37379547 | Review paper: the role of inflammation in mouse pulmonary neoplasia |
| Q55002130 | Serum osteopontin in patients with lung cancer and chronic obstructive pulmonary disease: does the co-existence make the difference? |
| Q36030691 | Squamous Metaplasia Is Increased in the Bronchial Epithelium of Smokers with Chronic Obstructive Pulmonary Disease |
| Q42753079 | Tailoring of corticosteroids in COPD management |
| Q36682108 | The National Cancer Institute's PREVENT Cancer Preclinical Drug Development Program: overview, current projects, animal models, agent development strategies, and molecular targets |
| Q45998753 | The effects of inhaled and oral corticosteroids on serum inflammatory biomarkers in COPD: an exploratory study. |
| Q37839576 | The epithelial cell and lung cancer: the link between chronic obstructive pulmonary disease and lung cancer |
| Q55003550 | The link between chronic obstructive pulmonary disease phenotypes and histological subtypes of lung cancer: a case-control study. |
| Q53394257 | The partners--airflow obstruction, emphysema, and lung cancer. |
| Q36346745 | The use of corticosteroids in patients with COPD or asthma does not decrease lung squamous cell carcinoma |
| Q30498384 | The validity of using ICD-9 codes and pharmacy records to identify patients with chronic obstructive pulmonary disease. |
| Q37115902 | Treatment of mild chronic obstructive pulmonary disease |
| Q22241904 | Update in lung cancer 2007 |
| Q53262672 | Use of systemic glucocorticoids and the risk of colorectal cancer. |
Search more.